Current and future role of carfilzomib‐based quadruplet combinations as therapy for newly diagnosed multiple myeloma
Authors:
- Ola LandgrenOLOla Landgren
- Noa BiranNBNoa Biran
- Elizabeth K. O'DOnnellEOElizabeth K. O'DOnnell
- Joseph MikhaelJMJoseph Mikhael
- Katja C. WeiselKWKatja C. Weisel
- Annemiek BroijlABAnnemiek Broijl
- Saad Z. UsmaniSUSaad Z. Usmani
- Philippe MoreauPMPhilippe Moreau
- Francesca M. GayFrancesca M. Gay
- Roberto MinaRMRoberto Mina
- Paula Rodríguez‐OteroPRPaula Rodríguez‐Otero
- Andrzej J. JakubowiakAJAndrzej J. Jakubowiak
Open Access
- 16 July 2025
- journal article
- review article
- Published by Wiley in HemaSphere
- Vol. 9 (7) , e70178
Abstract
The treatment of newly diagnosed multiple myeloma (NDMM) has advanced rapidly in recent years, with the standard of care (SOC) now including not only triplet combinations of proteasome inhibitors (PIs), immunomodulatory agents, and steroids but also quadruplet combinations that add the anti‐CD38 monoclonal antibodies isatuximab (Isa) or daratumumab (D) to a triplet backbone. In addition to the widely used bortezomib–lenalidomide–dexamethasone (VRd) combination, an alternative triplet option that can be considered is the combination of the second‐generation PI carfilzomib (K) with lenalidomide–dexamethasone (KRd). In patients with transplant‐eligible NDMM, US treatment guidelines have included the KRd triplet as a recommended regimen and the quadruplet combinations of either Isa‐KRd or D‐KRd as additional options. However, currently, KRd does not have regulatory approval for use in the NDMM population. This review describes the current evidence for using KRd as a backbone of therapy in frontline treatment regimens for patients with NDMM. In addition to multiple studies that have examined the KRd triplet in this population, several clinical trials have been investigating anti‐CD38‐KRd quadruplets. The data reported from these various trials are revealing deep and durable responses with Isa‐KRd and D‐KRd, including minimal residual disease negativity. Importantly, these benefits have also been demonstrated in high‐risk NDMM populations. KRd‐based combinations may represent a suitable alternative to VRd for some patients. This article discusses measures that may help to establish KRd‐based quadruplets as an additional SOC in this setting, including proper patient selection, steps to mitigate safety concerns, and the establishment of optimal dosing schedules.Keywords
This publication has 57 references indexed in Scilit:
- Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trialThe Lancet Haematology, 2017
- Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical TrialsJournal of Clinical Oncology, 2017
- Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple MyelomaJAMA Oncology, 2015
- Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with MyelomaNew England Journal of Medicine, 2014
- IMWG consensus on risk stratification in multiple myelomaLeukemia, 2013
- A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myelomaBlood, 2012
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2012
- Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)Blood, 2010
- Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimensBlood, 2009
- Stem Cell MobilizationHematology-American Society Hematology Education Program, 2003